Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Phospholipase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Phospholipase. Displaying page 1 of 1.
    EudraCT Number: 2007-000969-37 Sponsor Protocol Number: AN-SCD1121 Start Date*: 2007-10-05
    Sponsor Name:Anthera Pharmaceuticals Incorporated
    Full Title: IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk ...
    Medical condition: Acute Chest Syndrome (ACS) in At-Risk patients with Sickle Cell Disease (SCD) and Vaso-occlusive Crisis (VOC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051895 Acute chest syndrome LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005473-36 Sponsor Protocol Number: Dezember2014Version2 Start Date*: Information not available in EudraCT
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: Modeling of lipoprotein in patients with familial hypercholesterolemia compared to healthy subjects
    Medical condition: familial hypercholesterolemia
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006115-59 Sponsor Protocol Number: GNM-2011 Start Date*: 2012-06-11
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: "A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)"
    Medical condition: MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10018372 Glomerulonephritis membranous PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024064-18 Sponsor Protocol Number: OM-EPA-003 Start Date*: 2011-03-22
    Sponsor Name:Omthera Pharmaceutical Inc.
    Full Title: Efficacy and Safety of Epanova® in Severe Hypertriglyceridemia
    Medical condition: Severe hypertriglyceridemia defined as serum triglyceride (TG) values ≥500 and <2000 mg/dL (≥5.65 mmol/L and <22.60 mmol/L).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-003859-12 Sponsor Protocol Number: 12-027 Start Date*: 2013-07-19
    Sponsor Name:RWTH Aachen University for the Medical Faculty, represented by Clinical Trial Center Aachen (CTC-A)
    Full Title: Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus
    Medical condition: patients with type 2 diabetes mellitus and vascular inflammation
    Disease: Version SOC Term Classification Code Term Level
    17.0 10018065 - General disorders and administration site conditions 10061218 Inflammation PT
    17.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006697-15 Sponsor Protocol Number: D3560L00068 Start Date*: 2007-03-27
    Sponsor Name:AstraZeneca SAS
    Full Title: Evaluation de l'efficacité et de la tolérance de rosuvastatine 5 mg versus pravastatine 40 mg et atorvastatine 10 mg chez des patients hypercholestérolémiques de type IIa et IIb
    Medical condition: Hypercholestérolémies de type IIa et IIb
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020602 Hypercholesteremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-003590-24 Sponsor Protocol Number: LPL104884 Start Date*: 2006-03-01
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: LPL104884: A multicenter, randomized, double-blind, placebocontrolled, parallel-group, dose-ranging study of SB-480848, an oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in subje...
    Medical condition: SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) EE (Completed) HU (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000311-87 Sponsor Protocol Number: FFC-0001 Start Date*: 2012-04-23
    Sponsor Name:Fundación Fernández-Cruz
    Full Title: A long-term, randomized, open-labeled, parallel-group trial to compare the effects of liraglutide and sulphonilurea both in combination with metformin on clinical, endothelial and image markers of ...
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005855-19 Sponsor Protocol Number: BCX9930-211 Start Date*: 2021-10-11
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy
    Medical condition: complement 3 glomerulopathy immunoglobulin A nephropathy primary membranous nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    21.1 10038359 - Renal and urinary disorders 10027170 Membranous nephropathy LLT
    20.0 10038359 - Renal and urinary disorders 10077827 C3 glomerulopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-005317-68 Sponsor Protocol Number: ACE-CL-208 Start Date*: 2016-05-16
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
    Medical condition: High Risk Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001556-20 Sponsor Protocol Number: SB-480848/026 Start Date*: 2005-11-01
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Integrated Biomarker and Imaging Study – 2 (IBIS-2)
    Medical condition: SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DE (Completed) AT (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA